COMP <GO>
ADMA vs RXRX // ALTMAN Z-SCORE & DEBT/EQUITY
ADMA Biologics Inc (NASDAQ) VS. Recursion Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: ADMA 10
— RXRX 1
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: ADMA
LAST: $11.06 (-3.07%) • MKT CAP: $2.48B
balance-sheet
12.98
LAST: $3.83 (-4.96%) • MKT CAP: $2.29B
balance-sheet
1.59
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADMA VS. RXRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADMA | RXRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 57.40% | 5.00% | +52.40 | ADMA | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 32.90% | -35.00% | +67.90 | ADMA | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.4x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.06% | -14.95% | +16.01 | ADMA | /fcf-yield <GO> |
| Operating Margin | 37.50% | -60.00% | +97.50 | ADMA | /operating-margins <GO> |
| Net Profit Margin | 28.80% | -60.00% | +88.80 | ADMA | /net-margins <GO> |
| Revenue Growth (YoY) | 19.60% | 26.90% | -7.30 | RXRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 12.98 | 1.59 | +11.39 | ADMA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 4/9 | +3.00 | ADMA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.6 | 47.8 | +6.80 | ADMA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.00 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 15.0x | 32.0x | -17.00 | ADMA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.48B | $2.29B | $191.2M | ADMA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADMA REV | RXRX REV | ADMA GROSS % | RXRX GROSS % | ADMA FCF | RXRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $510.2M | $74.7M | 57.4% | 5.0% | $27.8M | -$378.3M |
| FY 2024 | $426.5M | $58.8M | 51.5% | 23.1% | $110.4M | -$372.9M |
| FY 2023 | $258.2M | $44.6M | — | — | $8.8M | -$289.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADMA // BETA —
RXRX // BETA 1.00